news
Boehringer Ingelheim announces results from one of its HCV Phase III trials
23 April 2013 | By Boehringer Ingelheim
Results from the pivotal Phase III STARTVerso™1 trial...
List view / Grid view
Boehringer Ingelheim
article
A pragmatic approach for the adoption of QbD principles for analytical method development and validation
18 April 2013 | By Heike Gottschalg, Rüdiger Gössl, Holger Memmesheimer and Holger-Thorsten Steinführer, Boehringer Ingelheim Pharma GmbH & Co KG
The principles of the application of Quality by Design (QbD) in the pharmaceutical industry in terms of development, manufacturing and control are well defined and described in the ICH guidelines Q8, Q9 and Q10. These guidelines mainly focus on the quality of the drug products, their manufacturing processes and the…
news
Argenta announces integrated drug discovery collaboration with Boehringer Ingelheim
17 April 2013 | By Zyme Communications
Argenta has signed a collaboration agreement with Boehringer Ingelheim...
news
Boehringer Ingelheim and Eli Lilly and Company announce acceptance of EMA application for investigational Type 2 Diabetes treatment empagliflozin*
26 March 2013 | By Ogilvy HealthPR London
“We are pleased with the promising results..."
news
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
26 March 2013 | By Boehringer Ingelheim
A new perspective from the U.S. FDA...
news
Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria
19 March 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy.…
news
American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013
11 March 2013 | By Boehringer Ingelheim
International peer-to-peer sharing...
news
Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients
11 March 2013 | By Boehringer Ingelheim
New data presented...
news
Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C
4 March 2013 | By Boehringer Ingelheim
Interim study results from STARTversoTM 4...
news
Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia
28 February 2013 | By Boehringer Ingelheim
Boehringer Ingelheim invests in rare diseases...
news
Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status
23 February 2013 | By Boehringer Ingelheim
New Phase III data presented...
news
New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism
21 February 2013 | By Boehringer Ingelheim
Findings from two trials...
news
FDA Advisory Committee recommends approval of olodaterol* for maintenance treatment of COPD
29 January 2013 | By Boehringer Ingelheim
Olodaterol may provide a new treatment option in patients with COPD...
news
Boehringer Ingelheim and the EFSD call for grant applications in diabetes research
17 January 2013 | By Boehringer Ingelheim
Submissions opened for diabetes research grant applications from across Europe...
news
Boehringer Ingelheim enrols first patients in pivotal Phase III interferon-free hepatitis C trial programme
17 January 2013 | By Boehringer Ingelheim
"Diabetes affects more than 371m people..."
